Why has Shilpa Medicare rallied so sharply in the last few days?
Answer
Answer
Shilpa Medicare rallied 10% after the CEO confirmed that the company had the capacity to manufacture 100-200 million doses of COVID vaccines. Shilpa has not confirmed if it would work with AstraZeneca or RDIF for Sputnik-V vaccine.
Both vaccines are based on recombinant technology combining DNA from a virus with bacterial cells to produce purified proteins so capacity is flexible. Shilpa manufactures APIs, which are pharma inputs, and it can manufacture vaccines at its Dharwad facility.